tiziana-logo.png
Tiziana Life Sciences PLC ("Tiziana" or the "Company") - PDMR Dealing
November 18, 2020 10:16 ET | Tiziana Life Sciences Plc
LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics...
tiziana-logo.png
Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease
November 11, 2020 02:00 ET | Tiziana Life Sciences Plc
First Ever Study with take-home capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody Potential to be a safer and effective alternative to the intravenous immunotherapies currently used...
tiziana-logo.png
Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
November 02, 2020 02:00 ET | Tiziana Life Sciences Plc
Highly innovative first-in-class study for treating COVID-19 disease with nasally administered drugTrial facilitated with collaboration of Harvard Medical School and one of the world’s top...
tiziana-logo.png
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
October 27, 2020 12:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics...
tiziana-logo.png
Tiziana Life Sciences Plc (the "Company") - Result of General Meeting
October 02, 2020 07:00 ET | Tiziana Life Sciences Plc
LONDON, Oct. 02, 2020 (GLOBE NEWSWIRE) -- At the General Meeting of the Company (Nasdaq: TLSA / AIM: TILS) held at 11.00 a.m. on 2 October 2020, both of the resolutions were duly passed. The...
tiziana-logo.png
Tiziana Life Sciences Interview to Air on Bloomberg International on The RedChip Money Report
September 25, 2020 02:00 ET | Tiziana Life Sciences Plc
LONDON and NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics...
tiziana-logo.png
Tiziana Life Sciences plc: Publication of Research Note
September 21, 2020 09:51 ET | Tiziana Life Sciences Plc
LONDON and NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), is pleased to note the publication of a new analyst...
tiziana-logo.png
Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil
September 17, 2020 02:00 ET | Tiziana Life Sciences Plc
Nasal Administration of Foralumab is a potentially transformative approach for treating patients with Covid-19 NEW YORK and LONDON, Sept. 17, 2020 (GLOBE NEWSWIRE) --  Tiziana Life Sciences plc...
tiziana-logo.png
Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, Accustem Sciences
September 16, 2020 06:00 ET | Tiziana Life Sciences Plc
NEW YORK and LONDON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted...
tiziana-logo.png
Tiziana Life Sciences Plc ("Tiziana" or the "Company") - Demerger of StemPrintER and Distribution in Specie
September 16, 2020 02:00 ET | Tiziana Life Sciences Plc
LONDON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Plc (LSE: TILS, NASDAQ: TLSA) a biotechnology company focussed on innovative therapeutics for oncology, inflammation and infectious...